Stabilized amorphous state of riluzole by immersion-rotavapor method with synthesized mesoporous SBA-15 carrier to augment in-vitro dissolution

Abstract

Abstract Mesoporous silica nanoparticles (MSNs) carriers have been considered as a promising approach for stabilizing the amorphous state of loaded drugs. MSNs are significantly improving the dissolution rate of poorly soluble drug candidates. The purpose of this study was to improve the rate of dissolution of the poorly water-soluble drug riluzole via amalgamation into Santa Barbara Amorphous type material (SBA-15) materials. A novel formulation is processed via the immersion-rotavapor method for riluzole (RLZ) with mesoporous SBA-15 submicron particles. The drug-loaded mesoporous silica nanoparticles were assessed by different characterization methods: scanning electron microscopy and differential scanning calorimetry. RLZ/SBA-15 unveiled superiority in the production of stable amorphous RLZ with a significantly enhanced rate of dissolution. Most drug molecules were entrapped, with drug loading of RLZ/SBA-15 ratio being 1:1 (w/w), inside the mesoporous channels via the immersion-rotavapor method. RLZ confined inside the mesoporous structure was in the amorphous state shown by DSC measurements. The uniform pore walls were thought to avert the recrystallization of the homogeneously distributed drug molecules inside the mesoporous structure. Remarkably, SBA-15 released the RLZ around 98.51 ± 2.01% in 8 h, whereas RLZ crystal showed only the dissolution of 39.57%. The dissolution rate of RLZ from the SBA-15 matrix was significantly improved. Henceforth, SBA-15 may become a capable platform for improving the RLZ oral bioavailability.